Guardant Health, Inc. (NASDAQ:GH) Director Stanley J. Meresman Sells 4,934 Shares


Share on StockTwits

Guardant Health, Inc. (NASDAQ:GH) Director Stanley J. Meresman sold 4,934 shares of the company’s stock in a transaction dated Monday, January 11th. The stock was sold at an average price of $142.00, for a total transaction of $700,628.00. Following the sale, the director now directly owns 8,993 shares of the company’s stock, valued at approximately $1,277,006. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Guardant Health stock opened at $159.36 on Thursday. The business has a 50 day moving average of $128.69 and a 200-day moving average of $105.13. Guardant Health, Inc. has a 1 year low of $55.90 and a 1 year high of $163.42. The company has a market capitalization of $15.93 billion, a P/E ratio of -83.43 and a beta of 0.58.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.44). Guardant Health had a negative net margin of 67.14% and a negative return on equity of 19.22%. The firm had revenue of $74.66 million during the quarter, compared to analyst estimates of $65.99 million. During the same period in the prior year, the company earned ($0.14) EPS. The business’s quarterly revenue was up 22.8% compared to the same quarter last year. As a group, equities research analysts predict that Guardant Health, Inc. will post -2.05 EPS for the current fiscal year.

GH has been the subject of several research analyst reports. BidaskClub downgraded Guardant Health from a “strong-buy” rating to a “buy” rating in a research note on Monday, December 28th. JPMorgan Chase & Co. boosted their target price on Guardant Health from $120.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, November 6th. Stifel Nicolaus initiated coverage on Guardant Health in a research note on Monday. They set a “buy” rating and a $175.00 target price for the company. Canaccord Genuity boosted their target price on Guardant Health from $145.00 to $170.00 in a research note on Tuesday. Finally, BTIG Research boosted their target price on Guardant Health from $132.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, December 17th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $140.91.

Hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System boosted its holdings in Guardant Health by 3.6% in the third quarter. California State Teachers Retirement System now owns 132,503 shares of the company’s stock valued at $14,811,000 after acquiring an additional 4,633 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Guardant Health by 32.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 254,133 shares of the company’s stock valued at $20,618,000 after acquiring an additional 62,145 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Guardant Health by 121.2% in the third quarter. DekaBank Deutsche Girozentrale now owns 42,250 shares of the company’s stock valued at $4,700,000 after acquiring an additional 23,150 shares during the last quarter. NEXT Financial Group Inc bought a new position in shares of Guardant Health during the 3rd quarter worth approximately $78,000. Finally, Lord Abbett & CO. LLC boosted its holdings in shares of Guardant Health by 4.1% during the 3rd quarter. Lord Abbett & CO. LLC now owns 300,427 shares of the company’s stock worth $33,581,000 after buying an additional 11,811 shares in the last quarter. Institutional investors and hedge funds own 76.15% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

Further Reading: How to track put option volume

Insider Buying and Selling by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.